M-Vax: an autologous, hapten-modified vaccine for human cancer

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

2001 • 2,365 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

2001 • 905 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations

1997 • 699 citations

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1999 • 495 citations

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

2002 • 387 citations

The First 1000 Dendritic Cell Vaccinees

2003 • 277 citations

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

1986 • 255 citations

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study

2000 • 250 citations

Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma

2001 • 243 citations

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

1987 • 224 citations

Immunopharmacologic Analysis of an Autologous, Hapten-Modified Human Melanoma Vaccine

2003 • 142 citations

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.

1997 • 128 citations

Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.

1984 • 124 citations

T Cell Recognition of Haptens, a Molecular View

1994 • 122 citations

Generation of Dendritic Cells In Vitro From Peripheral Blood Mononuclear Cells With Granulocyte-Macrophage-Colony-Stimulating Factor, Interleukin-4, and Tumor Necrosis Factor-α for Use in Cancer Immunotherapy

1997 • 108 citations

THE PRODUCTION OF THYROIDITIS AND ANTIBODY FOLLOWING INJECTION OF UNALTERED THYROGLOBULIN WITHOUT ADJUVANT INTO RABBITS PREVIOUSLY STIMULATED WITH ALTERED THYROGLOBULIN

1965 • 82 citations

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

1991 • 76 citations

Multiple cancers. Tumor burden permits the outgrowth of other cancers.

1985 • 74 citations

Expression of cytokine mRNA in human melanoma tissues

1995 • 73 citations

Treatment of metastatic melanoma with autologous, hapten‐modified melanoma vaccine: Regression of pulmonary metastases

2001 • 71 citations

Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

1995 • 71 citations

Enhanced Humoral Immune Response Correlates With Improved Disease-Free and Overall Survival in American Joint Committee on Cancer Stage II Melanoma Patients Receiving Adjuvant Polyvalent Vaccine

2002 • 60 citations

A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.

2003 • 41 citations

Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine

1994 • 37 citations

TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine

2002 • 20 citations

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

2002 • 13 citations

Deleted Work

1955 • 0 citations